Microbiome And Multi'Omics In Preterm Birth: The Bacteria And Birth Study (BaBs)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02392650|
Recruitment Status : Active, not recruiting
First Posted : March 19, 2015
Last Update Posted : May 11, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Hominids and hominins serve as remarkable hosts to microbes, and we have co-evolved over the past 4.5 million years as highly plethoric communities. Human-associated microorganisms (the "microbiome") are present in numbers exceeding the quantities of human cells by at least 10-fold beginning in the neonatal period. The collective genome (the "metagenome") exceeds our human genome in terms of gene content by more than 150-fold. With respect to microbiota and preterm birth, it has generally assumed that the majority of intrauterine infections originate in the lower genital tract, with microbiota ascending into the otherwise sterile intrauterine environment to infect the placenta (preterm birth), fetal membranes (chorioamnionitis), umbilical cord (funisitis), and the fetus (sepsis). However, we and others have recently demonstrated that the vaginal and gut microbiome communities are distinctly structured in pregnancy, and the placenta is in fact not sterile, but rather harbors a low-abundance microbiome which is likely acquired through hematogenous transmission of the oral microbiome.
Based on our prior studies and preliminary data, our central hypothesis is that a distinct and largely commensal resident microbiome in pregnancy renders risk for preterm birth. By utilizing our state-of-the-science technology and analysis tools in a longitudinal case-cohort of preterm birth subjects, we will be able to transform "discovery based" metagenomics and multi'omics science into readily translatable mechanistic studies at a previously unparalleled level.
|Condition or disease|
Specific Aim 1. Longitudinal maternal (vaginal, oral, skin, gut), fetal (oral, skin, gut) and placental (basal plate and parenchyma) 16S-based metagenomic profiling with inferred metagenomics will reveal distinct microbial communities in association with preterm birth. Methods: We will enroll 526 at-risk gravidae to yield an approximated 135 preterm births with 401 at-risk term controls. Starting in the first/early second trimester, we will sample multiple body sites (vagina, oral, stool, placenta) at multiple time points (antenatal through delivery), isolate microbial DNA, and perform 16S-based determination of niche-specific microbial communities found in association with preterm birth. With our case-cohort longitudinal design, we will be able to apply our well-developed supervised learning approaches to reveal which taxa contribute to risk of preterm birth, and at what body sites and gestational ages they are predictive of preterm birth.
Specific Aim 2. Whole-genome shotgun (WGS) metagenomics from selected subjects and body sites will enable species identification, generation of microbial gene catalogues, and metabolic reconstructions to determine the structure, function and diversity of the preterm birth microbiome. Methods: To probe metabolic functionality and describe pathogen-related mechanisms, we will analyze changes in total gene content using shotgun metagenomics on a subset of samples. We will build on our functional computational pipelines to fully characterize targeted subjects' metagenomic signatures.
Specific Aim 3. Integrated host genomics, metatranscriptomics and metabonomics data will reveal molecular mechanisms and networks underlying preterm birth in a limited subset of samples. Methods: We will interrogate and integrate our concomitantly acquired clinical metadata, microbial and host gene expression data (RNA-Seq metatranscriptomics), and metabonomics profiling with advanced computational and biostatistical approaches. We will be guided in our choice of subjects by our data from Aims 1 and 2.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||526 participants|
|Target Follow-Up Duration:||10 Years|
|Official Title:||Microbiome And Multi'Omics In Preterm Birth: The Bacteria And Birth Study (BaBs)|
|Actual Study Start Date :||June 2014|
|Estimated Primary Completion Date :||December 2024|
|Estimated Study Completion Date :||June 2025|
- Characterization of Maternal-Fetal microbiome [ Time Frame: Conception to 4-6 weeks postpartum ]Longitudinally characterize the maternal, placental, and infant microbiome in a cohort at risk of preterm birth. Not all the women will ultimately deliver preterm; we we will be able to see if there are microbiome changes associated with preterm birth.
- Association of maternal microbiome (gut, oral, vaginal, placenta) with preterm birth [ Time Frame: Conception to 4-6 weeks postpartum ]Longitudinally characterize the maternal, placental, and infant microbiome in a cohort at risk of preterm birth. Not all the women will ultimately deliver preterm; we we will be able to see if there are microbiome changes associated with preterm birth.
- Rate of Preterm Birth [ Time Frame: Conception to date of date of delivery, <37 weeks ]Measure rate of preterm birth <37 and <34 weeks gestation, as defined by best obstetrical estimate of last menstrual period consistent with <24 week sonogram, OR <24 week sonogram with unknown last menstrual period, OR skilled examination and <24 week sonogram
- Rate of Term Birth [ Time Frame: Conception to date of date of delivery ]Measure rate of term birth, as defined by best obstetrical estimate of last menstrual period consistent with <24 week sonogram, OR <24 week sonogram with unknown last menstrual period, OR skilled examination and <24 week sonogram
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||16 Years to 64 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
- Gravidae at risk for preterm birth, defined as: History of prior spontaneous preterm birth at 16w0d-36w6d gestational age confirmed by review of medical records. If efforts to retrieve medical records are unsuccessful, eligibility will depend upon the events surrounding the prior birth and birthweight under 2 kg; Documented shortened cervix <2.5 cm by transvaginal ultrasound performed by experienced sonographer at <24 weeks gestational age; Documented and culture-proven complicated lower or upper urinary tract infection defined as a urinary tract infection requiring hospitalization (e.g., pyelonephritis); Documented periodontal disease, treated or untreated; Documented recurrent lower genital infection; Smoking or other chemical dependency that would convey an increased risk of preterm birth; Other clinical concern for high risk of preterm birth (and cleared by PI Dr. Aagaard at BCM or Dr. Saade at UTMB)
- Enrollment at less than or equal to 20 weeks gestation by best obstetrical estimate
- Able to speak English or work with an interpreter
- Cognitively aware enough to be able to participate in the study
- Gravidae with viable pregnancy >10 weeks gestational age
- Willingness to consent to all required aspects of protocol - There will be additional non-required aspects that we will recruit 20% of subjects to participate in. These will be voluntary opt-in aspects
- 16 years of age or older
- Multifetal gestation at any time during the pregnancy
- Known HIV or Hepatitis C infection
- Known immunosuppressive disease
- Use of any of the following drugs within the last 6 months; Cytokines; Methotrexate or immunosuppressive cytotoxic agents
- History of cancer except for squamous or basal cell carcinomas of the skin or thyroid cancer that have been managed and fully treated.
- Major surgery of the GI tract (including gastric bypass), with the exception of cholecystectomy and appendectomy in the past five years. Any major bowel resection at any time. If conditions arise that require such surgeries during participation in the study, subjects will not be excluded after enrollment. If patient develops need for such surgery after enrollment, they will not be excluded.
- Documented chronic GI disorders, (e.g., Crohn's diseae)
- Chronic conditions with GI symptoms, (e.g. cystic fibrosis)
- Autism spectrum disorder or significant developmental delay, psychosis, major depressive disorder, or a history of bipolar disorder if there is concern about ability to consent
- Treatment for or suspicion of ever having had toxic shock syndrome.
- Fatal fetal anomaly. Will exclude after enrollment if not previously identified
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02392650
|United States, Texas|
|Baylor College of Medicine|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Kjersti Aagaard, MD/PhD||Associate Professor / Vice Chair for Research|
|Responsible Party:||Kjersti Aagaard, Associate Professor, Maternal-Fetal Medicine and Vice Chair for Research at Baylor College of Medicine, Baylor College of Medicine|
|Other Study ID Numbers:||
|First Posted:||March 19, 2015 Key Record Dates|
|Last Update Posted:||May 11, 2023|
|Last Verified:||May 2023|
Obstetric Labor, Premature
Obstetric Labor Complications
Female Urogenital Diseases and Pregnancy Complications